Maliha George, Townsend Raymond R
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
J Am Soc Hypertens. 2015 Jan;9(1):48-53. doi: 10.1016/j.jash.2014.11.001. Epub 2014 Nov 12.
The sodium glucose co-transporter 2 (SGLT2) inhibitors represent a promising treatment option for diabetes and its common comorbidity, hypertension. Emerging data suggests that the SGLT2 inhibitors provide a meaningful reduction in blood pressure, although the precise mechanism of the blood pressure drop remains incompletely elucidated. Based on current data, the blood pressure reduction is partially due to a combination of diuresis, nephron remodeling, reduction in arterial stiffness, and weight loss. While current trials are underway focusing on cardiovascular endpoints, the SGLT2 inhibitors present a novel treatment modality for diabetes and its associated hypertension as well as an opportunity to elucidate the pathophysiology of hypertension in diabetes.
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂是治疗糖尿病及其常见合并症高血压的一种很有前景的选择。新出现的数据表明，SGLT2抑制剂能显著降低血压，尽管血压下降的确切机制仍未完全阐明。根据目前的数据，血压降低部分归因于利尿、肾单位重塑、动脉僵硬度降低和体重减轻的综合作用。虽然目前正在进行关注心血管终点的试验，但SGLT2抑制剂为糖尿病及其相关高血压提供了一种新的治疗方式，也为阐明糖尿病中高血压的病理生理学提供了一个契机。
